AbbVie Inc.
NYSEABBV gained nearly 6% on the week to close at $263.04 — the stock's second consecutive week of meaningful outperformance against a peer group that continues to struggle. Last week's note flagged the peer divergence as the story. That story has deepened. AMGN dropped another 4.5% this week after its 15% collapse the prior week. VRTX and INCY…
ABBV cost to borrow surges to 0.50%, up 157% in one week — sharpest rise since late July despite falling short interest and plentiful available shares.
A new long-form analysis for ABBV this week — anomalies vs the company's own history, peer comparisons, news context, and the full data picture. Premium subscribers only.
Read on ORTEX →Sign up for premiumABBV gained nearly 6% on the week to close at $263.04 — the stock's second consecutive week of meaningful outperformance against a peer group that continues to struggle. Last week's note flagged the peer divergence as…
Snapshot as of 20 Sept 2026
ABBV is sending a clear message: the sellers are done. Short interest fell 19% in a week to just 1.06% of free float — a multi-month low — while options traders swung sharply toward calls, pushing the put/call ratio to…
ABBV has pulled back 3.2% this week to $250.94 — its first meaningful retreat since the mid-June trough — arriving just days after Q2 results that the analyst community greeted with fresh target raises but the market…
ABBV goes into Thursday's Q2 report having already cleared most of the analyst target cluster — the question now is whether the numbers can hold the stock at altitude. The broader positioning picture is remarkably calm…
ABBV enters the final stretch before its July 27 Q2 report having added 12% in a month, with the analyst community and the options market both pointing in the same direction. Options positioning offers the clearest…
ABBV has added another $1.60 since Sunday's recovery note and now trades at $256.10 — six days from a Q2 earnings print that has become the most anticipated catalyst on the pharma calendar this month. The analyst…
ABBV closed Tuesday at $244.78, down 4% from the July 10 close cited in last week's note — and the Street's response has been to keep raising targets anyway. The analyst upgrade wave that defined last week's story has…
ABBV has pulled back one percent on the day to close at $251.64, but that modest retreat comes after a stunning 7% weekly gain — and the underlying positioning still tells a bullish story heading into July 27…
ABBV has reclaimed the narrative after Sunday's Apogee acquisition shock, rallying 5.5% on the week to $234.76 as short sellers extend their retreat and options traders rotate back toward calls. The short position has…
ABBV has given back a few dollars from last week's peak but remains up nearly 5% on the week at $225.42, and the most interesting development is not the price — it's a sharp divergence between options traders leaning…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for ABBV — free to start on ORTEX.
Sign up for free →Open ABBV on ORTEX